Laboratory of Infectious Diseases, Clinical Research Program

Established in 1942, the NIAID Laboratory of Infectious Diseases (LID) has a long history of discovering new agents of viral diseases and developing innovative vaccines and treatments. The following are examples of Food and Drug Administration-approved medical advances in which LID scientists played a crucial role:

  • FluMist, a nasal spray influenza vaccine licensed by MedImmune
  • Synagis, a preventative treatment for respiratory syncytial virus licensed by MedImmune
  • Havrix, a hepatitis A vaccine licensed by GlaxoSmithKline

Current LID Clinical Research Studies Seeking Volunteers

LID clinical research teams could not make medical accomplishments without volunteers. We invite you to help us continue making potentially lifesaving medical discoveries. The following trials are seeking volunteers:

LID Clinical Studies Unit (CSU)

In recent years, the LID CSU has initiated efforts to perform uncommon and difficult, but necessary clinical studies to evaluate novel vaccines and therapeutics particularly universal influenza vaccines in the human challenge model and extremely novel universal vaccines for vector borne disease like Dengue, Zika, and Leishmaniasis. See LID CSU clinical trials and studies that are seeking volunteers.

Content last reviewed on March 29, 2019